Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...

In a report released on March 31, Andrew Berens from Leerink Partners maintained a Hold rating on IDEAYA Biosciences (IDYA – Research Report).

Fintel reports that on April 2, 2025, Leerink Partners upgraded their outlook for Compass Therapeutics (NasdaqCM:CMPX) from Market Perform to Outperform. Analyst Price Forecast Suggests 419.11% Upside ...

Leerink Partners analyst Puneet Souda maintained a Hold rating on Hologic (HOLX – Research Report) on March 28. The company’s shares opened ...

AirSculpt Technologies (NASDAQ:AIRS – Get Free Report) had its price target decreased by equities research analysts at Leerink Partners from $6.50 to $2.50 in a research note issued to investors on ...

Trump has repeatedly called April 2 “Liberation Day,” alluding to a more sweeping and aggressive set of tariffs. Leerink Partners analysts said that the risks from Trump’s tariffs on the biopharma ...

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) had its price objective dropped by Leerink Partners from $19.00 to $18.00 ...

SAN DIEGO, March 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place ...

will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET. A live webcast of the presentation may be accessed via the Investors ...